Dr. Martin A. Denbar’s clinical case series documents interfaced therapy using TAP-PAP interface with TAP oral appliance
DALLAS Aug 11, 2026 – TAP Sleep Care® today highlighted clinical evidence on Combination Therapy for CPAP-Resistant Obstructive Sleep Apnea from Martin A. Denbar, DDS, DABDSM, Diplomate of the American Board of Dental Sleep Medicine and Adjunct Assistant Professor in the Department of Internal Medicine at Texas A&M School of Medicine (Texas Dental Sleep Services). The evidence demonstrates that interfaced combination therapy using the TAP-PAP interface and TAP 3 Triple Laminate oral appliance effectively treats severe obstructive sleep apnea (OSA) in patients intolerant of conventional CPAP.
In three cases of severe OSA (baseline AHI 72.3–84.4), therapy reduced AHI by a mean of 95% to therapeutic levels (<5 events/hour), with moderate average pressures (~11.4 cmH₂O) These findings are drawn from three cases in a single clinical practice and are not a controlled trial.
Nightly use across the three cases ranged from 6 hours 38 minutes to 9 hours 39 minutes, above the 4-hour threshold commonly used for reimbursement. The cases included a diabetic patient with obesity (AHI reduced 95% to 4.2) and a super-obese patient with multiple comorbidities who first trialed the TAP 3 Triple Laminate oral appliance alone, with oximetry confirming an inadequate response. Once the TAP-PAP interface was added, her AHI fell 95% to 4.1 on the first night and reached 2.1 at two weeks. In the third case, a 73-year-old patient with a normal BMI reduced her AHI 93% to 4.7 on the first night of therapy and used the device 9 hours 39 minutes that same night. Benefits extended beyond AHI control to improved oxygenation and resolution of symptoms such as chronic fatigue.
“This data reinforces what we see every day: TAP-PAP combination therapy gives clinicians a proven, comfortable option for the most challenging CPAP-resistant patients,” said Charles Collins, CEO of TAP Sleep Care / Airway Management. “By pairing our TAP oral appliances with the TAP-PAP interface, we help restore healthy sleep and reduce the repetitive apneic events associated with cardiovascular strain for people who previously had limited alternatives.”
The strapless nasal-pillow design eliminates headgear, lowers required pressures, reduces leaks, and allows greater sleep-position freedom—driving higher real-world adherence than traditional CPAP in this population.
Dr. Denbar has used combination therapy in clinical practice for more than 30 years.
“For patients with severe obstructive sleep apnea who cannot or will not use conventional CPAP, the clinical stakes are high, and the treatment options have been limited,” noted Dr. Denbar. “For CPAP-intolerant patients with severe OSA, interfaced combination therapy using the TAP-PAP interface with the TAP 3 Triple Laminate oral appliance deserves consideration as a primary option, not a fallback.”
View the full release here.
